Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells

Bone Marrow Transplantation

Volumn 23, Issue 8, 1999, Pages 809-817

  Hoppe, B ^b   Mohr, M ^a   Roots Weiss A ^b   Kienast, J ^a   Berdel, W E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Westfälische Wilhelms Univ ^*

Author keywords

Autotransplantation; CD34 selection; Immunomagnetic double selection; Peripheral hematopoietic stem cells; Tumor cell purging

Indexed keywords

CD34 ANTIGEN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL SELECTION; CELL SEPARATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032891891     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701656     Document Type: Article

References (44)

1. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
4. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131-1137.
5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
6. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
7. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheralblood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
8. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation vs autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
9. Ager S, Scott MA, Mahendra P et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 79-83.
10. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
11. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
12. Diel IJ, Kaufmann M, Costa SD et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1659.
13. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
14. Mapara MY, Körner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337-344.
15. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
16. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
17. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606-1614.
18. Brockstein B, Ross A, Hollingsworth K et al. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced breast cancer patients undergoing high dose chemotherapy (HDC). Proc ASCO 1995; 14: 327 (Abstr. 975).
19. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
20. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
21. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
22. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-383.
23. Kvalheim G. Purging of autografts: methods and clinical significance. Ann Med 1996; 28: 167-173.
24. + cell separation systems. Bone Marrow Transplant 1997; 19: 1239-1246.
25. Bertolini F, Thomas T, Battaglia M et al. A new 'two step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplant 1997; 19: 615-619.
26. Paulus U, Schmitz N, Viehmann K et al. Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant 1997; 20: 415-420.
27. Butcher EC, Weissman IL. Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. I. Technical aspects. J Immunol Meth 1980; 37: 97-108.
28. Reynolds CP, Black AT, Woody JN. Sensitive method for detecting viable cells seeded into bone marrow. Cancer Res 1986; 46: 5878-5881.
29. + hematopoietic cells. Int J Oncol 1996; 9: 1107-1112.
30. Pedrazzoli P, Battaglia M, Da Prada GA et al. Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 167-169.
31. Vogler WR, Berdel WE, Olson AC et al. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood 1992; 80: 1423-1429.
32. Koenigsmann MP, Notter M, Knauf WU et al. Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant 1996; 18: 549-557.
33. Shpall EJ, Bast RC, Joines WT et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 7: 145-151.
34. Dietzfelbinger HF, Kühn D, Zafferani M et al. Removal of breast cancer cells from bone marrow by in vitro purging with either lipids and cryopreservation. Cancer Res 1993; 53: 3747-3751.
35. Anderson IC, Shpall EJ, Leslie DS et al. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989; 49: 4659-4664.
36. + cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. J Hematother 1995; 4: 539-544.
37. Dietzfelbinger HF, Lang A, Oberberg D et al. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells. Exp Hematol 1992; 20: 178-183.
38. Shpall EJ, Jones RB, Bast RC et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
39. Passos-Coelho J, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994; 54: 2366-2371.
40. Myklebust AT, Godal A, Juell S et al. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994; 54: 209-214.
41. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; I: 70-73.
42. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
43. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
44. Vredenburgh J, Shpall EJ, Ross M et al. Immunopharmacologic bone marrow purging and high-dose chemotherapy with autologous bone marrow support (ABMS) for patients with metastatic breast cancer. Proc ASCO 1992; 11: 58 (Abstr.58).